Guy Rutter1

Professor of Medicine Université de Montréal, Imperial College London, Nanyang Technological University Singapore. Wellcome Investigator.

[Guy Rutter1 @guy_rutter]

Our appreciation in Diabetologia of Steve Ashcroft who sadly passed away in November. Steve made fundamental contributions to our understanding of beta cell glucose sensing including the substrate site hypothesis and the role of KATP channels.

[Guy Rutter1 @guy_rutter]

@AidaMartinezS @SSunehera @ralen30 Delighted to be involved Aida! It’s a significant achievement to have described a pathway: glucose-AMPK-miR129b-MTFP1-mitochondrial ultrastructure and to show its relevance from living mice to human beta cells. #GiadaOstenilli @CRCHUM @CRCHUM_CELLS

[NSERC / CRSNG @NSERC_CRSNG]

📢
#CIHR, #NSERC and #SSHRC are proud to launch the new Canada Impact+ Research Training Awards to support the recruitment of international doctoral students and postdoctoral researchers to Canada.

Learn more about this new initiative:

▶️ https://t.co/3yGgK0vFUY

[TIPS_SPIIE @TIPS_SPIIE]

📢Today, the #GC launched new programs to attract international researchers to Canada.

✅ Canada Impact+ Research Chairs
✅ Canada Impact+ Emerging Leaders

Get all the details here: https://t.co/TswUTv30F0

@SSHRC_CRSH @NSERC_CRSNG
@CIHR_IRSC @InnovationCA @ISED_CA

[Guy Rutter1 @guy_rutter]

Leveraging the inhibition of disallowed beta cell genes as a therapeutic strategy!

[Daniel J Drucker @DanielJDrucker]

LDHA inhibition could be a novel therapeutic strategy for #diabetes treatment https://t.co/f1S5nGhDFs @DiabetologiaJnl

[Mark Carney @MarkJCarney]

Canada’s new government is investing big to attract world-class talent in science and technology — and become an innovation powerhouse.

[Eric Topol @EricTopol]

29%—That's a lot of weight loss, folks
Triple GLP-1 drug receptor retatrutide
Compares with avg weight loss with Zepbound 21%, Wegovy (Ozempic) 15%
https://t.co/6tSvT4K6TO

[Guy Rutter1 @guy_rutter]

ER calcium stores contribute to glucose-induced Ca2 waves and interce... https://t.co/v7d7BNxhYA Revisiting an old question with new tools! @L_F_D_S #BillLouch @CRCHUM @CRCHUM_CELLS @wellcometrust @CIHR_IRSC @BT1D_CA

[Gilles Gouspillou @GGouspillou]

Impaired cAMP–PKA–CREB1 signalling drives mitochondrial dysfunction in skeletal muscle during cancer cachexia | Nature Metabolism https://t.co/MIDnjMgrsG

[Guy Rutter1 @guy_rutter]

Out today in Diabetes! Additive Effects of Dorzagliatin and Glucagon-Like Peptide-1 Receptor Agonism in a Novel Mouse Model of GCK-MODY and in Obese db/db Mice | Diabetes | American Diabetes Association ⁦@CRCHUM⁩ ⁦@ImperialMDR⁩ https://t.co/JrmpZ8TV3O

[Nature Metabolism @NatMetabolism]

#Throwback

REVIEW | @guy_rutter , @BennyScience et al

Exploring pancreatic beta-cell subgroups and their connectivity

https://t.co/AaT8evxbXa

[Guy Rutter1 @guy_rutter]

Relaunching our @CRCHUM Cardiometabolic Axis data sessions data sessions today with amazing talks from #mathiasguayasamin and #luisdelgadillosilva. #ciaranmurphyroyal @CRCHUM_CELLS

[Dr. Alice Cheng @AliceYYCheng]

Not one, but TWO endocrinologists to join the Canadian Medical Hall of Fame in 2026. Both Drs Hegele and Zinman have changed the way we treat metabolic disorders forever. In addition though … they are just kind humans. Congratulations!!🎉🎊🎈

[Guy Rutter1 @guy_rutter]

Important new review from my @CRCHUM colleague #MarcDonath

[Daniel J Drucker @DanielJDrucker]

Inflammation is a key driver of the pathophysiology of cardiometabolic disorders #obesity #T2D and new metabolic medicines based on GLP-1 action exert their magic in part by reducing inflammation. A new review from Professor Donath summarizes the field https://t.co/7mDWLvqvyw

[LKCMedicine Research @lkcmedresearch]

I‑BET151 modulates glucokinase gene expression and beta cellfunction in part through changes in FOXO1 expression https://t.co/lh5MehpAGz

Assoc. Prof Yusuf Ali's team @NTU_LKCMedicine in collaboration with @guy_rutter and @astar_research discovered that BET protein inhibition (I-BET151) impacts pancreatic β-cell function.
🔹 ↑ Glucose excursions
🔹 ↓ Insulin response
🔹 Downregulation of MODY genes (Hnf4α, Gck, Hnf1α, Glut2) & PI3K–Akt pathway
⚠️ BET therapies may impair β-cell health — caution warranted.

#Diabetes #Epigenetics #BETinhibition

[Guy Rutter1 @guy_rutter]

All true.
But the same rigour should be applied to ALL the antibodies we use. Those against glucokinase are a case in point.

[David Hodson @daveyboyhod]

In some of these papers, glp1r detection is a small element. In others it's a large element. Don't trust antibody vendors, and do the legwork. As a field we are always happy to provide reagents/models to help with validation.

[Guy Rutter1 @guy_rutter]

Our new report with #YaChiHuang ⁦#MarjanRupnik using high-speed imaging in pancreatic slices. Pancreatic α-cells are functionally heterogeneous and sex-dependently regulated by neighboring endocrine cells | bioRxiv https://t.co/RuUVrMeIic

[Nature Metabolism @NatMetabolism]

#Throwback

REVIEW | @guy_rutter , @BennyScience et al

Exploring #pancreatic #BetaCell subgroups and their connectivity

https://t.co/AaT8evxJMI

[Guy Rutter1 @guy_rutter]

Our new kid on the block to rival or beat existing dual agonists? Binding kinetics, bias, receptor internalization and effects on insulin secretion in vitro and in vivo of a novel GLP-1R/GIPR dual agonist, HISHS-2001 - PubMed. https://t.co/nfGgPzhdT0

[Guy Rutter1 @guy_rutter]

The influence of metformin treatment on the circulating proteome - PubMed. Important new study led by ⁦@LeentHart⁩ and the EU-funded IMI -Rhapsody and IMI-DIRECT consortia https://t.co/grrqai12zA